PL2187882T3 - Leczenie postępującej choroby neurodegeneracyjnej ibudilastem - Google Patents
Leczenie postępującej choroby neurodegeneracyjnej ibudilastemInfo
- Publication number
- PL2187882T3 PL2187882T3 PL08781498T PL08781498T PL2187882T3 PL 2187882 T3 PL2187882 T3 PL 2187882T3 PL 08781498 T PL08781498 T PL 08781498T PL 08781498 T PL08781498 T PL 08781498T PL 2187882 T3 PL2187882 T3 PL 2187882T3
- Authority
- PL
- Poland
- Prior art keywords
- ibudilast
- treatment
- neurodegenerative disease
- progressive neurodegenerative
- progressive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92974507P | 2007-07-11 | 2007-07-11 | |
| US4218108P | 2008-04-03 | 2008-04-03 | |
| EP08781498A EP2187882B1 (en) | 2007-07-11 | 2008-07-08 | Treatment of progressive neurodegenerative disease with ibudilast |
| PCT/US2008/069417 WO2009009529A1 (en) | 2007-07-11 | 2008-07-08 | Treatment of progressive neurodegenerative disease with ibudilast |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2187882T3 true PL2187882T3 (pl) | 2013-05-31 |
Family
ID=39789775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08781498T PL2187882T3 (pl) | 2007-07-11 | 2008-07-08 | Leczenie postępującej choroby neurodegeneracyjnej ibudilastem |
Country Status (14)
| Country | Link |
|---|---|
| US (9) | US8138201B2 (pl) |
| EP (2) | EP2187882B1 (pl) |
| JP (2) | JP5468001B2 (pl) |
| CN (1) | CN101848712B (pl) |
| AU (1) | AU2008275148A1 (pl) |
| BR (1) | BRPI0814624A2 (pl) |
| CA (2) | CA2970273C (pl) |
| DK (1) | DK2187882T3 (pl) |
| ES (1) | ES2402175T3 (pl) |
| HR (1) | HRP20130057T1 (pl) |
| PL (1) | PL2187882T3 (pl) |
| PT (1) | PT2187882E (pl) |
| TW (1) | TW200918051A (pl) |
| WO (1) | WO2009009529A1 (pl) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2442651E (pt) * | 2009-06-19 | 2015-10-22 | Teva Pharma | Tratamento da esclerose múltipla com laquinimod |
| CA2766632A1 (en) | 2009-06-23 | 2010-12-29 | Medicinova, Inc. | Enantiomeric compositions of 2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one and related methods |
| DK2458992T3 (en) * | 2009-07-30 | 2016-02-08 | Teva Pharma | Treatment of crohn's disease with laquinimod |
| ES2586843T3 (es) * | 2009-08-10 | 2016-10-19 | Teva Pharmaceutical Industries Ltd. | Tratamiento de trastornos relacionados con BDNF usando laquinimod |
| CA2784394C (en) * | 2010-01-04 | 2016-12-13 | Mapi Pharma Limited | Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| KR20130014523A (ko) * | 2010-03-03 | 2013-02-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 및 메토트렉세이트의 병용에 의한 류마티스 관절염의 치료 |
| PL2542080T3 (pl) * | 2010-03-03 | 2017-02-28 | Teva Pharmaceutical Industries Ltd. | Leczenie toczniowego zapalenia stawów z zastosowaniem lakwinimodu |
| AU2011223692A1 (en) * | 2010-03-03 | 2012-10-25 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus nephritis using laquinimod |
| EP2699317B1 (en) | 2011-04-21 | 2016-08-10 | Mapi Pharma Limited | Random pentapolymer for treatment of autoimmune diseases |
| EA201490748A1 (ru) | 2011-10-12 | 2014-12-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение рассеянного склероза комбинацией лахинимода и финголимода |
| BR112014018485A8 (pt) | 2012-02-03 | 2017-07-11 | Teva Pharma | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf |
| CN103255142B (zh) * | 2012-02-21 | 2017-07-25 | 上海转基因研究中心 | 一种利用RNAi调控内源性朊蛋白表达的方法及其应用 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| CN103505731A (zh) * | 2012-06-15 | 2014-01-15 | 中国药科大学 | 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途 |
| FR3000746A1 (fr) | 2013-01-04 | 2014-07-11 | Centre Nat Rech Scient | Peptide pour son utilisation dans le traitement des neuronopathies motrices |
| BR112015019564A2 (pt) * | 2013-02-15 | 2017-07-18 | Teva Pharma | tratamento de esclerose múltipla com laquinimod |
| WO2014178892A1 (en) | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| CA2945978A1 (en) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| WO2015195822A1 (en) * | 2014-06-20 | 2015-12-23 | Medicinova, Inc. | A combination of geranylgeranylacetone and ibudilast and methods of using same |
| CA2961187A1 (en) * | 2014-09-16 | 2016-03-24 | Teva Pharmaceuticals Industries Ltd. | Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod |
| JP6827924B2 (ja) | 2014-11-26 | 2021-02-10 | メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． | イブジラスト及びリルゾールの組み合わせを含む医薬および組成物 |
| WO2016086000A1 (en) * | 2014-11-26 | 2016-06-02 | Medicinova, Inc. | A combination of geranygeranylacetone, ibudilast, and riluzole and methods of using same |
| CN105395511A (zh) * | 2015-12-07 | 2016-03-16 | 黑龙江省智诚医药科技有限公司 | 一种异丁司特缓释微丸及其制备方法 |
| US20190151294A1 (en) * | 2016-05-10 | 2019-05-23 | Medicinova, Inc. | Treatment of alcoholism and depression and/or dysphoric mood using ibudilast |
| WO2018119262A1 (en) * | 2016-12-22 | 2018-06-28 | Medicinova, Inc. | Methods of treating glioblastoma multiforme using ibudilast |
| CA3050086A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| US10744123B2 (en) | 2018-02-12 | 2020-08-18 | Medicinova, Inc. | Methods and dosing regimens using ibudilast and a second agent for cancer therapy |
| EP3740205B1 (en) * | 2018-02-12 | 2023-09-20 | MediciNova, Inc. | Methods of suppressing myeloid-derived suppressor cells in patients |
| US10946071B2 (en) | 2018-10-09 | 2021-03-16 | Medicinova, Inc. | Combination of ibudilast and interferon-beta and methods of using same |
| WO2020081941A1 (en) | 2018-10-19 | 2020-04-23 | Medicinova, Inc. | Methods of treating ophthalmic disease/disorder or injury with ibudilast |
| WO2020123861A1 (en) | 2018-12-12 | 2020-06-18 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| US20220160745A1 (en) * | 2019-02-26 | 2022-05-26 | Universitat De Valencia-Estudi General | Methods and compositions for treating motor neuron diseases |
| CA3130371A1 (en) | 2019-03-01 | 2020-09-10 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| US20220347159A1 (en) * | 2019-06-11 | 2022-11-03 | Yale University | Novel treatment for wolfram syndrome |
| EP4034090A1 (en) | 2019-09-23 | 2022-08-03 | MediciNova, Inc. | Ibudilast oral formulations and methods of using same |
| CN115335049A (zh) | 2020-04-06 | 2022-11-11 | 美迪诺亚公司 | 降低患者中巨噬细胞迁移抑制因子的血浆水平的方法 |
| EP4284366A1 (en) | 2021-01-29 | 2023-12-06 | MediciNova, Inc. | Methods of treating chemical gas exposure |
| US20230037014A1 (en) | 2021-07-26 | 2023-02-02 | Medicinova, Inc. | Methods of preventing cancer metastasis |
| US20230090534A1 (en) | 2021-09-21 | 2023-03-23 | Medicinova, Inc. | Methods of treating glioblastoma multiforme using combination therapy |
| WO2023150093A1 (en) | 2022-02-01 | 2023-08-10 | Medicinova, Inc. | Ibudilast for use in the treatment of post-covid conditions |
| WO2023192885A2 (en) * | 2022-03-28 | 2023-10-05 | Praxis Precision Medicines, Inc. | Methods of using oligomeric compounds to treat scn2a-related disorders |
| WO2024015415A1 (en) | 2022-07-13 | 2024-01-18 | Medicinova, Inc. | Injectable formulations of ibudilast |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE283047T1 (de) * | 1998-08-10 | 2004-12-15 | Kyorin Seiyaku Kk | Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose |
| WO2002045749A2 (en) | 2000-11-02 | 2002-06-13 | Research Foundation Of City University Of New York | Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| US20050043319A1 (en) * | 2001-08-14 | 2005-02-24 | Exonhit Therapeutics Sa | Molecular target of neurotoxicity |
| EP1689390B1 (en) | 2003-11-21 | 2011-02-09 | Zalicus Inc. | Methods and reagents for the treatment of inflammatory disorders |
| BRPI0518829A2 (pt) | 2004-12-06 | 2008-12-09 | Avigen Inc | mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas |
| EP1940389A2 (en) * | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
-
2008
- 2008-07-08 CA CA2970273A patent/CA2970273C/en active Active
- 2008-07-08 US US12/169,042 patent/US8138201B2/en active Active
- 2008-07-08 EP EP08781498A patent/EP2187882B1/en active Active
- 2008-07-08 JP JP2010516198A patent/JP5468001B2/ja active Active
- 2008-07-08 DK DK08781498.4T patent/DK2187882T3/da active
- 2008-07-08 CN CN200880106623XA patent/CN101848712B/zh active Active
- 2008-07-08 BR BRPI0814624-1A2A patent/BRPI0814624A2/pt not_active Application Discontinuation
- 2008-07-08 AU AU2008275148A patent/AU2008275148A1/en not_active Abandoned
- 2008-07-08 WO PCT/US2008/069417 patent/WO2009009529A1/en active Application Filing
- 2008-07-08 CA CA2693697A patent/CA2693697C/en active Active
- 2008-07-08 PT PT87814984T patent/PT2187882E/pt unknown
- 2008-07-08 ES ES08781498T patent/ES2402175T3/es active Active
- 2008-07-08 EP EP12196108A patent/EP2567699A1/en not_active Withdrawn
- 2008-07-08 PL PL08781498T patent/PL2187882T3/pl unknown
- 2008-07-10 TW TW097126065A patent/TW200918051A/zh unknown
-
2012
- 2012-02-22 US US13/402,702 patent/US8338453B2/en active Active
- 2012-12-21 US US13/725,627 patent/US9114136B2/en active Active
-
2013
- 2013-01-23 HR HRP20130057AT patent/HRP20130057T1/hr unknown
- 2013-12-10 JP JP2013255214A patent/JP2014062118A/ja active Pending
-
2014
- 2014-02-24 US US14/188,061 patent/US9314452B2/en active Active
- 2014-09-19 US US14/491,939 patent/US20150011581A1/en not_active Abandoned
-
2016
- 2016-03-23 US US15/078,291 patent/US20170014390A1/en not_active Abandoned
- 2016-10-07 US US15/288,582 patent/US20170020851A1/en not_active Abandoned
-
2019
- 2019-05-01 US US16/400,844 patent/US11083713B2/en active Active
-
2021
- 2021-07-02 US US17/366,563 patent/US11944607B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2187882T3 (pl) | Leczenie postępującej choroby neurodegeneracyjnej ibudilastem | |
| EP2320907A4 (en) | THERAPEUTIC COMPOUNDS | |
| EP2268285A4 (en) | THERAPEUTIC COMPOUNDS | |
| GB2464440B (en) | Massager | |
| GB0806794D0 (en) | Therapeutic compounds | |
| GB0813740D0 (en) | Therapeutic compounds | |
| ZA201202346B (en) | Therapeutic agent for mood disorders | |
| GB0700972D0 (en) | Treatment of inflammatory disease | |
| GB0804755D0 (en) | Therapeutic compounds | |
| EP2427183A4 (en) | THERAPEUTIC COMPOUNDS | |
| GB0720976D0 (en) | Treatment of inflammatory disease | |
| EP2554163A4 (en) | THERAPEUTIC ACTIVE FOR NEURODEGENERATIVE DISEASES | |
| GB0809476D0 (en) | Treatment of neurodegenerative disorders | |
| EP2182976A4 (en) | TREATMENT OF AUTOIMMUNE DISEASES | |
| EP2496704A4 (en) | THERAPEUTIC COMPOUNDS | |
| GB0723100D0 (en) | Treatment of HFnEF | |
| EP2456309A4 (en) | THERAPEUTIC COMPOUNDS | |
| EP2212701A4 (en) | NEW TREATMENT OF AUTOIMMUNE DISEASES | |
| GB0906026D0 (en) | Therapeutic compounds | |
| GB0819543D0 (en) | Treatment of proteostatic disease | |
| GB0817859D0 (en) | Treatment of proteostatic disease | |
| GB0701350D0 (en) | Therapeutic invention | |
| GB0919113D0 (en) | Therapeutic invention | |
| GB0908666D0 (en) | Treatment of proteostatic disease | |
| GB0907254D0 (en) | Combating disease |